Using Kaplan–Meier survival curves, it was confirmed in two independent databases that glioma patients with high FXYD2 mRNA expression had a longer survival time than patients with low expression from TCGA (P = 0.000, Fig. 6A) and REMBRANDT database (P = 0.000, Fig. 6B). The gene discussed is FXYD2; the disease is central nervous system cancer.